Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cyclerion Therapeutics Inc CYCN

Healthcare Biotechnology
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the... see more

Recent & Breaking News (NDAQ:CYCN)

Cyclerion Appoints Regina Graul, Ph.D., as President

GlobeNewswire December 4, 2023

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

GlobeNewswire November 30, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

GlobeNewswire July 31, 2023

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire June 1, 2023

Cyclerion Announces Reverse Stock Split

GlobeNewswire May 15, 2023

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

GlobeNewswire May 11, 2023

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

GlobeNewswire May 11, 2023

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

GlobeNewswire April 3, 2023

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

GlobeNewswire March 27, 2023

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

GlobeNewswire March 22, 2023

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

GlobeNewswire November 22, 2022

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

GlobeNewswire October 6, 2022

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

GlobeNewswire August 9, 2022

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

GlobeNewswire July 28, 2022

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

GlobeNewswire July 26, 2022

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

GlobeNewswire June 28, 2022

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

GlobeNewswire June 22, 2022

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

GlobeNewswire June 17, 2022

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

GlobeNewswire June 10, 2022

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

GlobeNewswire June 6, 2022